Retinopathy of Prematurity Market size is expected to reach USD 14 Million by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of retinopathy of prematurity was USD 9 Million. There has been a rise fir premature births which leads to abnormal development of retinal blood vessels due to an imbalance of certain growth factors in the eyes. According to the World Health Organization (WHO), an estimated 13.4 million babies were born too early in 2020.
In addition, the growing popularity and awareness of supportive care practices and efforts to build a conducive environment for preterm infants’ overall growth and organ maturation boost the market. Moreover, premature infants need careful monitoring, so regular health check-ups and vaccination of premature kids stimulate the retinopathy of the premature market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 5% |
|
Base Year Market Size (2023) |
~ USD 9 Million |
|
Forecast Year Market Size (2036) |
~ USD 14 Million |
|
Regional Scope |
|
Disease Type (Partial Retinal Detachment, Extra-Retinal Fibrovascular Proliferation, Total Retinal Detachment)
The partial retinal detachment segment in the retinopathy of prematurity market is estimated to gain the largest revenue share of about 56% in the year 2036. The segment growth can be attributed to factors that rise in cases of partial retinal detachment may necessitate specialized surgical procedures for effective treatment. This could lead to growth in the market for surgical equipment and expertise related to retinopathy of prematurity management. In addition, the diagnosis of partial retinal detachment in retinopathy of prematurity often requires advanced imaging technologies expertise which leads to demand for diagnostic tools that further stimulate segment growth.
End-User (Hospital, Clinic, Home Care)
The hospital segment is estimated to gain the largest market share of about 54% in the year 2036. The segment growth can be attributed to education provided by hospitals to caregivers about retinopathy of prematurity, its risk factors, and the importance of regular eye examinations for premature infants. In addition, hospitals become central in providing various treatment modalities related to retinopathy of prematurity and employ skilled healthcare professionals to carry out the interventions that stimulate segment growth. According to the National Library of Medicine, the incidence of retinopathy of prematurity ranges from 17% in the public hospital to 30% in private hospitals. About 4% preterm babies require treatment for retinopathy of prematurity.
Our in-depth analysis of the global market includes the following segments:
|
Disease Type |
|
|
End-User |
|
North American Market Forecast
Retinopathy of prematurity market in North America region is anticipated to hold the largest share of about 41% by the end of 2036. The regional growth is attributed to ongoing advancements in medical technology, a focus on early detection and intervention, and a commitment to improving outcomes for premature infants at risk of developing retinopathy of prematurity. In addition, growing awareness among people regarding neonatal imaging is further expected to propel the growth of the regional market. Moreover, AI is highly being used for the diagnosis of retinopathy of prematurity in newborns. According to Pharmaceutical Technology, nearly 80% of infants treated with Eylea experienced an absence of active retinopathy of prematurity and unfavorable structural outcomes at 52 weeks of age in both trials. AI in healthcare has effectively diagnosed a blindness-causing disease in premature newborns which led to growth in the market.
European Market Analysis
The Europe market is estimated to be the second largest, registering a share of about 35% by the end of 2036. The market’s expansion can be attributed to the patient-centric approach in which the shift towards patient-centric healthcare models such as gathering feedback from patient’s families allows healthcare providers to continuously improve services, adopt better strategies, and emphasize personalized treatment plans contributing to the growth of retinopathy of prematurity market in Europe. Moreover, healthcare providers in Europe aim to create personalized treatment plans based on the specific needs of each premature infant diagnosed with retinopathy of prematurity which further stimulates the market. In addition, efforts to standardize treatment protocols and guidelines for retinopathy of prematurity management ensure consistency in healthcare practices, driving market growth in the region through streamlined approaches.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?